67 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
of PATHFNDR-2 are incredibly exciting for both patients with acromegaly and the healthcare providers who treat them,” stated Monica R. Gadelha, M.D., Ph.D
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist
8-K
jsmh3la4mrga
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
u6wi9ih6rd
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
sheahynhhef9j7n
11 Sep 23
Regulation FD Disclosure
6:05am
UPLOAD
6sc0ngfrh08yn s1fe
20 Dec 22
Letter from SEC
12:00am
8-K
EX-99.1
khc8aj3o6 htqhzye
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
r26h9wzy
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
424B5
lxl7mi8z
13 Apr 22
Prospectus supplement for primary offering
4:22pm